Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
139
Biotechnology
Next Earning date - 27 Mar 2025
139
Biotechnology
Next Earning date - 27 Mar 2025
Relative Strenght
0Volume Buzz
1439%Earning Acce
YesDist 52w H.
99%